Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI

Table 3 Unadjusted and adjusted clinical outcomes according to HTR

			Unadjusted		Multivariable-Adjusted
	HTR (n = 4430)	Non-HTR (n = 5737)	HR (95% CI)	P value	HR (95% CI)	P value
Major adverse cardiac event^a	371 (8.4)	301 (5.2)	1.64 (1.41–1.91)	< 0.001	1.56 (1.34–1.82)	< 0.001
Device-oriented composite endpoint^b	258 (5.8)	212 (3.7)	1.62 (1.35–1.94)	< 0.001	1.52 (1.27–1.83)	< 0.001
All-cause death	68 (1.5)	66 (1.2)	1.34 (0.95–1.88)	0.093	1.33 (0.94–1.89)	0.112
Cardiac death	42 (0.9)	30 (0.5)	1.82 (1.14–2.90)	0.013	1.85 (1.13–3.03)	0.014
Myocardial infarction	123 (2.8)	73 (1.3)	2.20 (1.65–2.94)	< 0.001	2.05 (1.53–2.75)	< 0.001
Target vessel Myocardial infarction	58 (1.3)	31 (0.5)	2.45 (1.59–3.80)	< 0.001	2.18 (1.40–3.39)	0.001
Any revascularization	463 (10.5)	424 (7.4)	1.45 (1.27–1.66)	< 0.001	1.42 (1.24–1.62)	< 0.001
Target vessel revascularization	257 (5.8)	226 (3.9)	1.51 (1.26–1.80)	< 0.001	1.47 (1.22–1.76)	< 0.001
Target lesion revascularization	200 (4.5)	172 (3.0)	1.54 (1.26–1.89)	< 0.001	1.50 (1.22–1.84)	< 0.001
Definite or probable stent thrombosis	48 (1.1)	23 (0.4)	2.72 (1.65–4.46)	< 0.001	2.47 (1.49–4.10)	< 0.001
Stroke	92 (2.1)	74 (1.3)	1.61 (1.18–2.18)	0.002	1.47 (1.08–2.01)	0.015
Any bleeding	293 (6.6)	403 (7.0)	0.94 (0.81–1.09)	0.432	0.91 (0.78–1.06)	0.242
Clinically relevant bleeding^c	113 (2.6)	165 (2.9)	0.88 (0.70–1.12)	0.314	0.85 (0.66–1.08)	0.174

Values are number of events (%) unless otherwise indicated. The adjusted risk of adverse events after HTR versus non-HTR was assessed using a multivariable Cox proportional hazards regression adjusted for age, sex, current smoking, hyperlipidemia, hypertension, acute coronary syndrome, left ventricular ejection fraction, peripheral artery disease, previous myocardial infarction, previous revascularization (percutaneous coronary intervention and/or coronary artery bypass graft), hemoglobin, white blood cell count, platelet count, type of DES, and duration of DAPT. CI Confidence interval, HR Hazard ratio, HTR High thrombotic risk; other abbreviations as in Table 1 and Table 2
^a Major adverse cardiac events was defined as the composite of cardiac death, myocardial infarction, target vessel revascularization or definite/probable stent thrombosis
^b Device-oriented composite endpoint (DOCE) was defined as the composite of cardiac death, target-vessel myocardial infarction, and target lesion revascularization
^c Clinically relevant bleeding was defined as BARC type 2, 3, or 5 bleeding

ISSN: 1471-2261